1. Contents
   Pages A1-A4

2. Editorial Board
   Page A5

3. Information for Readers
   Page A6

Editorials

4. Learning from history: A commentary on the American Heart Association
Science Advisory on depression screening
   Pages 503-505
   Brett D. Thombs, Lisa R. Jewett, Ruby Knafo, James C. Coyne, Roy C. Ziegelstein

5. The high cost of nonadherence after percutaneous coronary intervention—Can
   health care reform solve this problem?
   Pages 506-508
   Debabrata Mukherjee

Trial Design

6. Rationale and design of China intensive lipid lowering with statins in acute
   coronary syndrome: The CHILLAS study
   Pages 509-512.e1
   Shui-ping Zhao, Dao-quan Peng, Bi-lian Yu, Yong Huo and the CHILLAS
   investigators

7. Design of the DEFINE trial: Determining the Efficacy and Tolerability of
   CETP Inhibition with AnacEtrapib
   Pages 513-519.e3
   Christopher P. Cannon, Hayes M. Dansky, Michael Davidson, Antonio M. Gotto Jr.,
   Eliot A. Brinton, A. Lawrence Gould, Michael Stepanavage, Sherry Xueyu Liu,
   Sukrut Shah, Joseph Rubino, Patrice Gibbons, Anne Hermanowski-Vosatka, Bruce
   Binkowitz, Yale Mitchel, Philip Barter and for the DEFINE investigators

8. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-
   eluting stents and paclitaxel-eluting stents in patients with coronary artery
   disease
   Pages 520-526.e2
   Eugenia Nikolsky, Alexandra J. Lansky, Krishnankutty Sudhir, Julie Doostzadeh,
   Donald E. Cutlip, Robert Piana, Xiaolu Su, Roseann White, Charles A. Simonton,
   Gregg W. Stone

9. Design and rationale of the TRI-stent Adjudication Study (TRIAS) Program
   Pages 527-532.e1
10. The Family Atherosclerosis Monitoring In Early life (FAMILY) study: Rationale, design, and baseline data of a study examining the early determinants of atherosclerosis

Katherine M. Morrison, Stephanie A. Atkinson, Salim Yusuf, Jacqueline Bourgeois, Sarah McDonald, Matthew J. McQueen, Richard Persadie, Barry Hunter, Janice Pogue, Koon Teo and the FAMILY investigators

11. Differential effects of afterload on left ventricular long- and short-axis function: Insights from a clinical model of patients with aortic valve stenosis undergoing aortic valve replacement

Shemy Carasso, Oved Cohen, Diab Mutlak, Zvi Adler, Jonathan Lessick, Shimon A. Reisner, Harry Rakowski, Gil Bolotin, Yoram Agmon

12. Hospital performance recognition with the Get With The Guidelines Program and mortality for acute myocardial infarction and heart failure

Paul A. Heidenreich, William R. Lewis, Kenneth A. LaBresh, Lee H. Schwamm, Gregg C. Fonarow

13. Cardiovascular events with absent or minimal coronary calcification: The Multi-Ethnic Study of Atherosclerosis (MESA)


Amir A. Mahabadi, Fabian Bamberg, Michael Toepker, Christopher L. Schlett, Ian S. Rogers, John T. Nagurney, Thomas J. Brady, Udo Hoffmann, Quynh A. Truong

15. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry

Tomasz Rakowski, Zbigniew Siudak, Artur Dziewierz, Ralf Birkemeyer, Jacek Legutko, Waldemar Mielecki, Rafal Depukat, Magnus Janson, Justyna Stefaniak, Krzysztof Zmudka, Jacek S. Dubiel, Lukasz Partyka, Dariusz Dudek
16. **Drug-eluting stents: A study of international practice**  
*Pages 576-584*  
David Austin, Keith G. Oldroyd, David R. Holmes Jr, Charanjit S. Rihal, P. Diane Galbraith, William A. Ghali, Victor Legrand, Yves Taeymans, Alex McConnachie, Jill P. Pell and on behalf of the APPROACH Investigators Belgian Working Group on Invasive Cardiology, Mayo Clinic PCI Registry, and Scottish Coronary Revascularisation Registry

17. **Timing of clopidogrel loading before percutaneous coronary intervention in clopidogrel-naive patients with stable or unstable angina: A comparison of two strategies**  
*Pages 585-591*  
Periklis A. Davlouros, Aggelos Arseniou, George Hahalis, John Chiladakis, Andreas Mazarakis, Anastasia Damelou, Marina Karakantza, Fotini Paliogianni, Nikolaos Karogiannis, Dimitrios Alexopoulos

18. **Patterns of use of thienopyridine therapy after percutaneous coronary interventions with drug-eluting stents and bare-metal stents**  
*Pages 592-598.e1*  
Dennis T. Ko, Maria Chiu, Helen Guo, Peter C. Austin, Jean-François Marquis, Jack V. Tu

19. **Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: Four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial**  
*Pages e43-e50*  
Emilio Di Lorenzo, Rosario Sauro, Attilio Varricchio, Michele Capasso, Tonino Lanzillo, Fiore Manganelli, Ciro Mariello, Francesco Siano, Maria Rosaria Pagliuca, Giovanni Stancio, Giuseppe Rosato, Giuseppe De Luca

Hypertension

20. **Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: The Studying the Treatment of Acute hyperTension (STAT) Registry**  
*Pages 599-606.e1*  
Jason N. Katz, Joel M. Gore, Alpesh Amin, Frederick A. Anderson, Joseph F. Dasta, James J. Ferguson, Kurt Kleinschmidt, Stephan A. Mayer, Alan S. Multz, W. Frank Peacock, Eric Peterson, Charles Pollack, Gene Yong Sung, Andrew Shorr, Joseph Varon, Allison Wyman, Leigh A. Emery, Christopher B. Granger and on behalf of the STAT Investigators

Genetics

21. **Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis**  
*Pages 607-614*  
Lawreen H. Connors, Tatiana Prokaeva, Amareth Lim, Roger Théberge, Rodney H. Falk, Gheorghe Doros, Alan Berg, Catherine E. Costello, Carl O'Hara, David C. Seldin, Martha Skinner

22. **Insertion/deletion polymorphism in α2-adrenergic receptor gene is a genetic**
risk factor for sudden cardiac death
Pages 615-621
Jari A. Laukkanen, Timo H. Mäkikallio, Jussi Kauhanen, Sudhir Kurl

Electrophysiology

23. Electrocardiographic predictors of atrial fibrillation
Pages 622-628
Marco V. Perez, Frederick E. Dewey, Rachel Marcus, Euan A. Ashley, Amin A. Al-Ahad, Paul J. Wang, Victor F. Froelicher

24. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study
Pages 629-636
Hiroshi Watanabe, Toru Watanabe, Shigeru Sasaki, Kojiro Nagai, Dan M. Roden, Yoshifusa Aizawa

Congestive Heart Failure

25. Drug-eluting versus bare-metal stents for treating saphenous vein grafts
Pages 637-643

Pages 644-652
Amrut V. Ambardekar, Gregg C. Fonarow, Adrian F. Hernandez, Wenqin Pan, Clyde W. Yancy, Mori J. Krantz and for the Get With the Guidelines Steering Committee and Hospitals

27. Blood transfusion for acute decompensated heart failure—friend or foe?
Pages 653-658
Moshe Garty, Eytan Cohen, Alexander Zuchenko, Solomon Behar, Valentina Boyko, Zaza Iakobishvili, Moshe Mittelman, Alexander Battler, Avraham Shotan, Shmuel Gottlieb, Avraham Caspi, David Hasdai and for the Heart Failure Survey in Israel (HFSIS) Investigators

28. Red cell distribution width in heart failure: Prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state
Pages 659-666
Zsolt Förhécz, Timea Gombos, Gábor Borgulya, Zoltán Pozsonyi, Zoltán Prohászka, Lívia János kutí

29. Correction
Page 666

30. Coffee consumption and risk of heart failure in men: An analysis from the Cohort of Swedish Men
Pages 667-672
Hanna N. Ahmed, Emily B. Levitan, Alicja Wolk, Murray A. Mittleman

Coronary Artery Disease
31. **Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: Data from The Heart and Soul Study**
   Pages 673-679
   Bill P.C. Hsieh, Adam M. Rogers, Beeya Na, Alan H.B. Wu, Nelson B. Schiller, Mary A. Whooley

32. **Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study**
   Pages e51-e57
   Ralf Köster, Jan Kaehler, Thomas Meinertz and for the REDUCTION Study Group

33. **Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery**
   Pages 680-687

34. **Characterization and outcomes of women and men with non–ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: Results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) Quality Improvement Initiative**
   Pages 688-694

Letter to the Editor

35. **Are we sure we have taken the best from clopidogrel?**
   Page e59
   Bernardo Cortese, Andrea Picchi, Andrea Micheli, Ugo Limbruno